Immunotherapy response-associated Akkermansia: canary in a coal mine?

Tina Cascone; Manoj Chelvanambi; Jennifer A Wargo

doi:10.1016/j.it.2022.03.007

Immunotherapy response-associated Akkermansia: canary in a coal mine?

Trends Immunol. 2022 May;43(5):337-339. doi: 10.1016/j.it.2022.03.007. Epub 2022 Apr 6.

Authors

Tina Cascone¹, Manoj Chelvanambi², Jennifer A Wargo³

Affiliations

¹ Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jwargo@mdanderson.org.

PMID: 35397955
DOI: 10.1016/j.it.2022.03.007

Abstract

Gut microbes can shape cancer immunotherapy responses; however, specific taxa have not been tested prospectively as biomarkers. Derosa and colleagues now demonstrate that the presence of Akkermansia muciniphila in baseline stool samples can be associated with improved outcomes and enhanced antitumor immune cell infiltrates in patients with lung cancer treated with immune checkpoint blockade (ICB).

MeSH terms

Akkermansia*
Humans
Immune Checkpoint Inhibitors
Immunologic Factors
Immunotherapy

Substances

Immune Checkpoint Inhibitors
Immunologic Factors

Grants and funding

R01 CA219896/CA/NCI NIH HHS/United States